Standard Biotools (LAB) Net Income towards Common Stockholders (2010 - 2026)

Standard Biotools (LAB) has 17 years of Net Income towards Common Stockholders data on file, last reported at $141.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 5420.84% year-over-year to $141.7 million in Q1 2026; TTM through Mar 2026 was $87.2 million, a 341.11% increase from a year earlier, with the FY2025 full-year figure at -$74.9 million, up 45.31% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $141.7 million, up from -$2.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for LAB reached as high as $153.2 million in Q4 2022 and fell as low as -$76.3 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$2.2 million across 5 years, with a median of -$17.7 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders sank 305.96% in 2022 and jumped 5420.84% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $153.2 million in 2022, then tumbled by 90.78% to $14.1 million in 2023, then decreased by 1.78% to $13.9 million in 2024, then sank by 115.63% to -$2.2 million in 2025, then jumped by 6632.69% to $141.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $141.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$34.7 million in Q3 2025.